Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System

Documents similaires

• Immune‐Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis
  par: Pooja Gokhale, et autres
  Publié: (2026)
• A Disproportionality Analysis of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Agents Using the FDA Adverse Event Reporting System Database
  par: Boyi Liu, et autres
  Publié: (2026)
• A Real‐World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System ( FAERS ) Database
  par: Yajing Xu, et autres
  Publié: (2025)
• Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer
  par: Natansh D. Modi, et autres
  Publié: (2025)
• Bridging FDA Adverse Event Reporting System ( FAERS ) and Clinical Practice: Comprehensive Characterization of Immune Checkpoint Inhibitors Toxicities in Geriatric Lung Cancer Patients
  par: Yumeng Tian, et autres
  Publié: (2026)